A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Sponsor: Clovis Oncology, Inc.
A PHASE2 clinical study on Advanced Lung Cancer and Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Clovis Oncology, Inc. and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Oct 2018 — Aug 2019 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clovis Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Aurora, United States, Barcelona, Spain, Caen, France, Essen, Germany, Großhansdorf, Germany, Lille, France, Los Angeles, United States, Marseille, France, Milan, Italy and 8 more location s